US 12,221,484 B2
Anti-NMDA receptor antibodies and methods of use
Scott K. Dessain, Wynnewood, PA (US); Rashmi Sharma, King of Prussia, PA (US); and Fetweh H. Al-Saleem, Philadelphia, PA (US)
Assigned to Lankenau Institute for Medical Research, Wynnewood, PA (US)
Appl. No. 17/599,399
Filed by Lankenau Institute for Medical Research, Wynnewood, PA (US)
PCT Filed Jun. 8, 2019, PCT No. PCT/US2019/036185
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/204977, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/826,552, filed on Mar. 29, 2019.
Prior Publication US 2022/0073611 A1, Mar. 10, 2022
Int. Cl. G01N 33/53 (2006.01); C07K 16/28 (2006.01); G01N 33/564 (2006.01)
CPC C07K 16/286 (2013.01) [G01N 33/564 (2013.01); G01N 2333/70571 (2013.01); G01N 2800/24 (2013.01)] 10 Claims
 
1. A recombinant, synthetic, or monoclonal human antibody or antigen binding fragment thereof that specifically binds to an N-methyl-D-aspartate Receptor (NMDAR) protein comprising the amino acid sequence of SEQ ID NO: 7, said antibody or antigen binding fragment thereof comprising:
i. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 11;
ii. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 12 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 13; or
iii. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 14 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO: 15,
wherein the antibody or antigen binding fragment thereof is coupled covalently or non-covalently to a detectable label.